MIRA
INFORM REPORT
|
Report Date : |
11.06.2014 |
IDENTIFICATION DETAILS
|
Name : |
BEIJING JOINTOWN PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
No. 9 Guangping Avenue, Daxing Economic Development Zone Daxing District, Beijing 102600 PR |
|
|
|
|
Country : |
China |
|
|
|
|
Financials (as on) : |
31.12.2013 |
|
|
|
|
Date of Incorporation : |
29.06.2000 |
|
|
|
|
Com. Reg. No.: |
110000001431587 |
|
|
|
|
Legal Form : |
One-Person Limited Liability Company |
|
|
|
|
Line of Business : |
Subject is engaged in selling drugs and medical devices. |
|
|
|
|
No of Employees : |
1,100 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2014
|
Country Name |
Previous Rating (31.12.2013) |
Current Rating (31.03.2014) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderate Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderate High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role - in 2010 China became the world's largest exporter. Reforms began with the phasing out of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China has implemented reforms in a gradualist fashion. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. After keeping its currency tightly linked to the US dollar for years, in July 2005 China moved to an exchange rate system that references a basket of currencies. From mid 2005 to late 2008 cumulative appreciation of the renminbi against the US dollar was more than 20%, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing allowed resumption of a gradual appreciation and expanded the daily trading band within which the RMB is permitted to fluctuate. The restructuring of the economy and resulting efficiency gains have contributed to a more than tenfold increase in GDP since 1978. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2013 stood as the second-largest economy in the world after the US, having surpassed Japan in 2001. The dollar values of China's agricultural and industrial output each exceed those of the US; China is second to the US in the value of services it produces. Still, per capita income is below the world average. The Chinese government faces numerous economic challenges, including: (a) reducing its high domestic savings rate and correspondingly low domestic consumption; (b) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and increasing numbers of college graduates; (c) reducing corruption and other economic crimes; and (d) containing environmental damage and social strife related to the economy's rapid transformation. Economic development has progressed further in coastal provinces than in the interior, and by 2011 more than 250 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of population control policy is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and economic development. The Chinese government is seeking to add energy production capacity from sources other than coal and oil, focusing on nuclear and alternative energy development. Several factors are converging to slow China's growth, including debt overhang from its credit-fueled stimulus program, industrial overcapacity, inefficient allocation of capital by state-owned banks, and the slow recovery of China's trading partners. The government's 12th Five-Year Plan, adopted in March 2011 and reiterated at the Communist Party's "Third Plenum" meeting in November 2013, emphasizes continued economic reforms and the need to increase domestic consumption in order to make the economy less dependent in the future on fixed investments, exports, and heavy industry. However, China has made only marginal progress toward these rebalancing goals. The new government of President XI Jinping has signaled a greater willingness to undertake reforms that focus on China's long-term economic health, including giving the market a more decisive role in allocating resources
|
Source
: CIA |
COMPANY NAME & ADDRESS
BEIJING JOINTOWN
PHARMACEUTICAL CO., LTD.
NO. 9 GUANGPING
AVENUE, DAXING ECONOMIC DEVELOPMENT ZONE
DAXING DISTRICT,
BEIJING 102600 PR CHINA
TEL: 86 (0)
10-60210555/60210968/60210244
FAX: 86 (0)
10-60210999/60210947
EXECUTIVE SUMMARY
Date of Registration : JUNE 29, 2000
REGISTRATION NO. : 110000001431587
LEGAL FORM : ONE-PERSON LIMITED LIABILITY COMPANY
REGISTERED CAPITAL : CNY 219,800,000
staff :
1,100
BUSINESS CATEGORY : trading
Revenue : CNY 4,566,609,000 (AS OF DEC. 31, 2013)
Equities :
CNY 405,630,000 (AS OF DEC. 31, 2013)
WEBSITE : http://www.yyjzt.com/jzteyao/lib/qyxingxiang/beijingjzt/qyjj.htm
E-MAIL :
N/A
PAYMENT :
AVERAGE
MARKET CONDITION : COMPETITIVE
FINANCIAL CONDITION : stable
OPERATIONAL TREND : STEADY
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE :
CNY 6.24 = USD 1
Adopted
abbreviations (as follows)
SC - Subject Company
(the company inquired by you)
N/A – Not available
CNY – China Yuan Ren
Min Bi
OPERATIONAL TREND & GENERAL REPUTATION
This section aims at indicating the relative positions of SC in respect
of its operational trend & general reputation
Operational Trend:- General
Reputation:-
Upward Excellent
Steady Good
Fairly Steady Fairly
Good
Ordinary Average
Fair Fair
Stagnant Detrimental
Downward Not
known
Not known Not
yet be determined
Not yet be determined
LEGAL STATUS & HISTORY
SC was established
as a limited liabilities company of PRC on June 29, 2000. However, SC changed
to present legal form, and was registered as one-person limited liabilities
company of PRC with State Administration for Industry & Commerce (SAIC) under
registration No.: 110000001431587 since June 2006.
SC’s Organization Code Certificate No.:
72267675-8
SC’s Tax No.: 110115722676758
SC’s registered capital: CNY 219,800,000
SC’s paid-in capital: CNY 219,800,000
Registration Change Record:-
|
Date |
Change of Contents |
Before the change |
After the change |
|
2000-8 |
Registered Capital |
CNY 500,000 |
CNY 3,000,000 |
|
2000-9 |
Registered Capital |
CNY 3,000,000 |
CNY 8,000,000 |
|
% of Shareholding |
Wuhan Junda Industry Co., Ltd. 70% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 25% Zhanjiang Yibao Pharmaceutical Co., Ltd. 5% |
Wuhan Junda Industry Co., Ltd. 70% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 28% Zhanjiang Yibao Pharmaceutical Co., Ltd. 2% |
|
|
2000-10 |
Registered Capital |
CNY 8,000,000 |
CNY 16,000,000 |
|
2000-11 |
Registered Capital |
CNY 16,000,000 |
CNY 24,000,000 |
|
% of Shareholding |
Wuhan Junda Industry Co., Ltd. 70% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 28% Zhanjiang Yibao Pharmaceutical Co., Ltd. 2% |
Wuhan Junda Industry Co., Ltd. 70% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 28.5% Zhanjiang Yibao Pharmaceutical Co., Ltd. 1.5% |
|
|
2002-1 |
Shareholder (s) (% of Shareholding) |
Wuhan Junda Industry Co., Ltd. 70% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 28.5% Zhanjiang Yibao Pharmaceutical Co., Ltd. 1.5% |
Wuhan Junda Industry Co., Ltd. 71.5% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 28.5% |
|
2002-3 |
Registered Capital |
CNY 24,000,000 |
CNY 30,000,000 |
|
Shareholder (s) (% of Shareholding) |
Wuhan Junda Industry Co., Ltd. 71.5% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 28.5% |
Wuhan Junda Industry Co., Ltd. 57.2% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 22.8% Shanghai Hongkang Industry Investment Co., Ltd. 20% |
|
|
2002-8 |
Registered Capital |
CNY 30,000,000 |
CNY 42,000,000 |
|
% of Shareholding |
Wuhan Junda Industry Co., Ltd. 57.2% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 22.8% Shanghai Hongkang Industry Investment Co., Ltd. 20% |
Wuhan Junda Industry Co., Ltd. 40.86% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 16.28% Shanghai Hongkang Industry Investment Co., Ltd. 42.86% |
|
|
2002-9 |
Registered Capital |
CNY 42,000,000 |
CNY 50,000,000 |
|
% of Shareholding |
Wuhan Junda Industry Co., Ltd. 40.86% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 16.28% Shanghai Hongkang Industry Investment Co., Ltd. 42.86% |
Wuhan Junda Industry Co., Ltd. 31.78% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 12.66% Shanghai Hongkang Industry Investment Co., Ltd. 55.56% |
|
|
2002-11 |
Shareholder (s) (% of Shareholding) |
Wuhan Junda Industry Co., Ltd. 31.78% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 12.66% Shanghai Hongkang Industry Investment Co., Ltd. 55.56% |
Wuhan Junda Industry Co., Ltd. 3.7% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 1.25% Shanghai Hongkang Industry Investment Co., Ltd. 52% Liu Zhaonian 43.05% |
|
2003-7 |
Shareholder (s) (% of Shareholding) |
Wuhan Junda Industry Co., Ltd. 3.7% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 1.25% Shanghai Hongkang Industry Investment Co., Ltd. 52% Liu Zhaonian 43.05% |
Wuhan Junda Industry Co., Ltd. 55.7% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 1.25% Liu Zhaonian 43.05% |
|
2003-11 |
Shareholder (s) |
Wuhan Junda Industry Co., Ltd. 55.7% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 1.25% Liu Zhaonian 43.05% |
Jiuzhoutong Group Co., Ltd. 55.7% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 1.25% Liu Zhaonian 43.05% |
|
2004-12 |
Shareholder (s) (% of Shareholding) |
Jiuzhoutong Group Co., Ltd. 55.7% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 1.25% Liu Zhaonian 43.05% |
Jiuzhoutong Group Co., Ltd.司 98.75% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 1.25% |
|
2006-6 |
Legal form |
Limited Liabilities Company |
One-Person Limited Liabilities Company |
|
Shareholder (s) (% of Shareholding) |
Jiuzhoutong Group Co., Ltd. 98.75% Hubei Jiuzhoutong Pharmaceutical Co., Ltd. 1.25% |
Jiuzhoutong Group Co., Ltd. 100% |
|
|
2008-4 |
Registration No. |
1100001143158 |
110000001431587 |
|
2008-6 |
Company Name |
Beijing Jiuzhou Tongda E- Business Co., Ltd. |
Beijing Jointown Pharmaceutical Co., Ltd. |
|
2008-12 |
Shareholder’s Name |
Jiuzhoutong Group Co., Ltd. |
Jointown Pharmaceutical Group Co., Ltd. |
|
2009-4 |
Registered capital |
CNY 50,000,000 |
CNY 110,000,000 |
|
2012 |
Registered Capital |
CNY 110,000,000 |
CNY 189,800,000 |
|
Legal Representative |
Liu Zhaonian |
Gong Li |
|
|
2013 |
Registered Capital |
CNY 189,800,000 |
CNY 219,800,000 |
Current Co search indicates SC’s shareholders & chief executives are
as follows:-
|
Name of Shareholder (s) |
% of Shareholding |
|
Jointown Pharmaceutical Group Co., Ltd. |
100 |
SC’s Chief Executives:-
|
Position |
Name |
|
Legal Representative and Chairman |
Gong Li |
|
General Manager |
Chen Zhijun |
|
Director |
Wen Xumin |
|
Supervisor |
Wan Yongjun |
RECENT DEVELOPMENT
No recent development was found during our checks at present.
SHAREHOLDER CHART & BACKGROUND
Name % of
Shareholding
Jointown Pharmaceutical Group Co., Ltd. 100
========================
Legal representative: Liu Baolin
Registration No.: 420000400000103
Registered capital: CNY 1,609,616,634
The said company is listed in Shanghai Stock
Exchange Market with the stock code 600998.
Add: No. 8 Longyang Avenue, Hanyang
District, Wuhan, Hubei Province
Tel: 86 027 84884488
Fax: 86 027 84860303
Web: www.jztey.com
MANAGEMENT
Gong Li, Legal
Representative and Chairman
-------------------------------------------------------------------
Ø
Gender: M
Ø
Age: 41
Ø
ID# 422202197305182411
Ø Qualification:
University
Ø Working experience
(s):
At present, working in SC as legal
representative and chairman
Also working in Jointown Pharmaceutical Group
Co., Ltd. as deputy general manager
Chen Zhijun,
General Manager
----------------------------------------------------
Ø
Gender: M
Ø Qualification:
University
Ø Working experience
(s):
At present, working in SC as general manager
Director
-----------
Wen Xumin
Supervisor
--------------
Wan Yongjun
BUSINESS OPERATION
SC’s registered
business scopes include wholesaling Chinese herbal medicine, Chinese medicine pieces,
Chinese medicine, chemical raw materials, chemical medicine preparation,
antibiotics, biochemical drugs, biological products, and the second class of
psychoactive drugs; selling health food, packaged food stereotypes, Ⅲ type of medical equipment:
medical ultrasound machines and related equipment; medical laser equipment;
physical therapy and rehabilitation equipment; injection needle devices,
medical polymer materials and products, medical suture materials and adhesives;
intervention equipment ; medical materials and dressings; cardiopulmonary
bypass and blood processing equipment; dental materials; the operating room,
emergency room, clinic equipment and apparatus; implant materials and
artificial organs; medical optical equipment, instruments and endoscopic
equipment; medical electronic equipment; silver clip; bone per pin; in vitro
diagnostic reagents; ophthalmic surgical instruments; medical high frequency
equipment; medical X-ray equipment; clinical laboratory analytical instruments;
Class Ⅱ medical devices:
Urinary anorectal surgical instruments; basic surgical instruments, injection
needle apparatus, general examination equipment, medical electronic equipment,
medical optical equipment, instruments and endoscopic equipment, medical ultrasound
machines and related equipment, physical therapy and rehabilitation equipment,
medicine equipment, medical X-ray equipment and ancillary components, clinical
testing analytical instruments, medical laboratory equipment and infrastructure
equipment, operating room, emergency room, clinic equipment and apparatus,
equipment and appliances ward care, disinfection and sterilization equipment
and apparatus, medical materials and dressings, suture materials and medical
adhesives, medical polymer materials and products, implant materials and
artificial organs; neurosurgery instruments; thoracic cardiovascular surgery
instruments; medical high-frequency equipment; orthopedic surgery (orthopedic)
surgery instruments; dental equipment and apparatus; medical cold treatment,
cryogenic, refrigeration equipment and apparatus; gingival retraction cord;
general cargo, cargo-specific transport (cold storage); internet information
services; using www.jzteyao.com.cn website Publishing online advertising;
selling daily necessities, household items, hygiene products, condoms,
contraceptive cap, early pregnancy test strip, pregnancy test pen, pregnancy
test kits, drug packaging materials and containers, cosmetics, medical devices
(Ⅰtype), chemicals
(excluding a class of hazardous chemicals and precursor chemicals); retailing
hippocampus, sea turtle products; designing and producing online advertising;
medical technology consulting (without intermediaries); warehousing services;
design, production, agent and release of advertising; import and export of
goods and technology; import and export agent.
SC is mainly
engaged in selling drugs and medical devices.
SC’s products mainly include: Chinese herbal medicine, Chinese medicine
pieces, Chinese medicine, Western medicine, the spirit of second-class
medicine, chemical raw materials, health products, health supplies, medical
equipment, etc.
SC sources its
products 95% from domestic market, and 5% from overseas market. SC sells 95% of
its products in domestic market, and 5% to overseas market.
The buying terms of SC include Check, T/T, L/C and Credit of 30-60 days.
The payment terms of SC include Check, T/T, L/C and Credit of 30-60 days.
Staff & Office:
--------------------------
SC is known
to have approx. 1,100 staff
at present.
SC owns an area as
its operating office, but the detailed information is unknown.
RELATED COMPANY
SC is known to invest in
the following companies:
Inner
Mongolia Jointown Pharmaceutical Co., Ltd.
Beijing
Jiuzhou Tongda Logistics Co., Ltd.
Tianjin
Jiuzhou Tongda Pharmaceutical Co., Ltd.
Beijing
Jiuzhou Tongda Pharmaceutical Co., Ltd.
Beijing
Jingfeng Pharmaceutical Co., Ltd.
Beijing
Jundagaoke Science & Technology Incubator Co., Ltd.
PAYMENT
Overall payment appraisal:
( ) Excellent ( ) Good (X) Average ( ) Fair ( ) Poor ( ) Not yet be determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment experience (through current enquiry with SC's
suppliers), our delinquent payment and our debt collection record concerning
SC.
Trade payment experience: SC did not
provide any name of trade/service suppliers and we have no other sources to conduct
the enquiry at present.
Delinquent payment record: None in our
database.
Debt collection record: No overdue amount
owed by SC was placed to us for collection within the last 6 years.
BANKING
The bank
information of SC is not filed in local SAIC.
FINANCIALS
Balance Sheet
|
Unit: CNY’000 |
As
of Dec. 31, 2009 |
As
of Dec. 31, 2010 |
|
159,935 |
62,961 |
|
|
Notes receivable |
9,018 |
30,287 |
|
Accounts
receivable |
176,659 |
130,616 |
|
Export drawback
receivable |
0 |
0 |
|
Advances to suppliers |
47,483 |
45,132 |
|
Other receivable |
45,836 |
147,302 |
|
Inventory |
302,499 |
297,323 |
|
Deferred expense |
0 |
0 |
|
Non-current
assets within one year |
0 |
0 |
|
Other current
assets |
0 |
0 |
|
|
------------------ |
------------------ |
|
Current assets |
741,430 |
713,621 |
|
Fixed assets |
110,787 |
118,952 |
|
Construction in
progress |
13,528 |
120 |
|
Intangible
assets |
28,774 |
25,996 |
|
Long-term
investment |
92,132 |
92,132 |
|
Deferred income
tax assets |
0 |
0 |
|
Other non-current
assets |
131 |
233 |
|
|
------------------ |
------------------ |
|
Total assets |
986,782 |
951,054 |
|
|
============= |
============= |
|
Short-term loans |
140,000 |
8,000 |
|
Notes payable |
281,078 |
47,689 |
|
Accounts payable |
156,103 |
178,424 |
|
Wages payable |
2,527 |
32 |
|
Taxes payable |
-1,679 |
7,855 |
|
Unpaid profits |
0 |
0 |
|
Advances from
clients |
14,546 |
14,620 |
|
Other payable |
141,597 |
519,666 |
|
Other current
liabilities |
0 |
0 |
|
|
------------------ |
------------------ |
|
Current
liabilities |
734,172 |
776,286 |
|
Non-current
liabilities |
63,000 |
2,970 |
|
|
------------------ |
------------------ |
|
Total
liabilities |
797,172 |
779,256 |
|
Equities |
189,610 |
171,798 |
|
|
------------------ |
------------------ |
|
Total
liabilities & equities |
986,782 |
951,054 |
|
|
============= |
============= |
Income Statement
|
Unit: CNY’000 |
As
of Dec. 31, 2009 |
As
of Dec. 31, 2010 |
|
Revenue |
2,605,938 |
2,779,073 |
|
Cost of sales |
2,475,139 |
2,630,522 |
|
Taxes and surcharges |
1,804 |
2,686 |
|
Sales expense |
36,913 |
54,645 |
|
Management expense |
37,111 |
36,075 |
|
Finance expense |
8,784 |
16,725 |
|
Asset impairment loss |
255 |
458 |
|
Investment
income |
24,075 |
10,498 |
|
Non-business
income |
2,129 |
6,267 |
|
Non-business expenditure |
91 |
248 |
|
Profit before
tax |
72,045 |
54,479 |
|
Less: profit tax |
2,270 |
10,943 |
|
69,775 |
43,536 |
Financial Summary
|
Unit: CNY’000 |
As
of Dec. 31, 2011 |
As
of Dec. 31, 2012 |
As
of Dec. 31, 2013 |
|
Total
liabilities |
-- |
1,057,500 |
1,473,050 |
|
Equities |
-- |
275,070 |
405,630 |
|
|
------------- |
------------- |
------------- |
|
Total assets |
1,191,580 |
1,332,570 |
1,878,680 |
|
|
------------- |
------------- |
------------- |
|
|
As
of Dec. 31, 2011 |
As
of Dec. 31, 2012 |
As
of Dec. 31, 2013 |
|
Revenue |
3,033,840 |
3,511,340 |
4,566,609 |
|
Profit before
tax |
55,070 |
63,660 |
72,075 |
|
Less: profit tax |
2,120 |
9,360 |
13,200 |
|
Profits |
52,950 |
54,300 |
58,875 |
Important Ratios
=============
|
|
2009 |
2010 |
2011 |
2012 |
2013 |
|
*Current ratio |
1.01 |
0.92 |
-- |
-- |
-- |
|
*Quick ratio |
0.60 |
0.54 |
-- |
-- |
-- |
|
*Liabilities
to assets |
0.81 |
0.82 |
-- |
0.79 |
0.78 |
|
*Net profit
margin (%) |
2.68 |
1.57 |
1.75 |
1.55 |
1.29 |
|
*Return on
total assets (%) |
7.07 |
4.58 |
4.44 |
4.07 |
3.13 |
|
*Inventory /
Revenue ×365 |
42 days |
39 days |
-- |
-- |
-- |
|
*Accounts
receivable / Revenue ×365 |
25 days |
17 days |
-- |
-- |
-- |
|
*Revenue /
Total assets |
2.64 |
2.92 |
2.55 |
2.64 |
2.43 |
|
*Cost of sales
/ Revenue |
0.95 |
0.95 |
-- |
-- |
-- |
FINANCIAL COMMENTS
PROFITABILITY:
FAIRLY GOOD
l The revenue of SC
appears fairly good, and it increased year by year.
l SC’s net profit
margin is average.
l SC’s return on
total assets is average.
l
SC’s cost of sales is fairly high, comparing with
its revenue.
LIQUIDITY: AVERAGE
l
The current ratio of SC is maintained in a normal
level.
l
SC’s quick ratio is maintained in a fair level.
l
The inventory of SC appears average
l
The accounts receivable of SC appears average.
l
SC’s short-term loans are in an average level.
l
SC’s revenue is in an average level, comparing with
the size of its total assets.
LEVERAGE: AVERAGE
l
The debt ratio of SC is average.
l
The risk for SC to go bankrupt is average.
Overall financial
condition of the SC: Stable.
CONCLUSIONS
SC is considered large-sized in its line with stable financial
conditions and good background.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 59.26 |
|
|
1 |
Rs. 99.62 |
|
Euro |
1 |
Rs. 80.59 |
INFORMATION DETAILS
|
Analysis Done by
: |
KRN |
|
|
|
|
Report Prepared
by : |
DPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.